Back to top

Analyst Blog

OncoGenex Pharmaceuticals, Inc. (OGXI - Snapshot Report) recently announced that it is looking to move its oncology candidate, OGX-427, into a phase II study, Spruce, for the potential treatment of previously untreated advanced non-squamous non-small cell lung cancer (NSCLC).

The investigator-sponsored, randomized, double-blind, placebo-controlled phase II study will evaluate whether progression-free survival (PFS) outcomes can be improved by adding OGX-427 to carboplatin and pemetrexed therapy.

In the Spruce study, patients with non-squamous NSCLC will be randomized to receive carboplatin and pemetrexed therapy plus either OGX-427 or placebo.

Spruce is the fifth phase II study being conducted with OGX-427 after Borealis-1, Borealis-2, Pacific and OGX-427-PR01. The Borealis-1 study is designed to evaluate the survival benefit, safety and tolerability of combining OGX-427 with gemcitabine and cisplatin in the first-line treatment of patients with advanced bladder cancer. The Borealis-2 study is being conducted in patients suffering from advanced or metastatic bladder cancer whose disease has progressed following initial platinum-based chemotherapy treatment.

The Pacific study is evaluating the benefit of OGX-427 plus Johnson & Johnson’s (JNJ - Analyst Report) Zytiga in men with castration-resistant prostate cancer (CRPC) while OGX-427-PR01 is evaluating the benefit of OGX-427 plus prednisone in CRPC patients.

The most advanced candidate in OncoGenex’ pipeline is custirsen, which is being studied for three indications under phase III trials, namely, Affinity (second-line CRPC), Enspirit (advanced NSCLC) and Synergy (chemotherapy - naive CRPC)

OncoGenex has a global collaboration and license agreement with Teva Pharmaceutical Industries Ltd. (TEVA - Analyst Report) for custirsen.

OncoGenex and Teva currently carry a Zacks Rank #3 (Hold). Currently, companies like UCB look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
HI CRUSH PA… HCLP 68.05 +4.74%
CTPARTNERS… CTP 12.91 +3.12%
QIHOO 360 T… QIHU 90.56 +3.11%
HOLLYSYS AU… HOLI 22.85 +2.97%
BONANZA CRE… BCEI 61.57 +2.94%